Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.

Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C, Chandesris MO, Acin Y, Létard S, de Sepulveda P, Hermine O, Bernard OA, Dubreuil P.

Blood. 2012 Dec 6;120(24):4846-9. doi: 10.1182/blood-2011-12-397588. Epub 2012 Oct 16.

2.

Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.

De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA.

PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014.

3.

Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.

Gerbaulet A, Wickenhauser C, Scholten J, Peschke K, Drube S, Horny HP, Kamradt T, Naumann R, Müller W, Krieg T, Waskow C, Hartmann K, Roers A.

Blood. 2011 Feb 10;117(6):2012-21. doi: 10.1182/blood-2008-11-189605. Epub 2010 Dec 9.

4.

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG.

Leukemia. 2009 May;23(5):900-4. doi: 10.1038/leu.2009.37. Epub 2009 Mar 5.

5.

Molecular defects in mastocytosis: KIT and beyond KIT.

Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, Damaj G, Dubreuil P, Arock M.

Immunol Allergy Clin North Am. 2014 May;34(2):239-62. doi: 10.1016/j.iac.2014.01.009.

PMID:
24745672
6.

SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Hanssens K, Brenet F, Agopian J, Georgin-Lavialle S, Damaj G, Cabaret L, Chandesris MO, de Sepulveda P, Hermine O, Dubreuil P, Soucie E.

Haematologica. 2014 May;99(5):830-5. doi: 10.3324/haematol.2013.095133. Epub 2014 Jan 3.

7.

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I.

Nat Genet. 1996 Mar;12(3):312-4.

PMID:
8589724
8.

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.

Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD.

Exp Hematol. 2003 Aug;31(8):686-92.

PMID:
12901973
9.
10.

KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A.

Blood. 2006 Oct 1;108(7):2366-72. Epub 2006 Jun 1.

11.

Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.

Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Møller MB; Mastocytosis Centre Odense University Hospital (MastOUH).

Eur J Haematol. 2012 Jul;89(1):42-6. doi: 10.1111/j.1600-0609.2012.01789.x. Epub 2012 Apr 28.

PMID:
22469616
12.

KIT and mastocytosis.

Lim KH, Pardanani A, Tefferi A.

Acta Haematol. 2008;119(4):194-8. doi: 10.1159/000140630. Epub 2008 Jun 20. Review.

PMID:
18566536
13.

A new c-kit mutation in a case of aggressive mast cell disease.

Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M.

Br J Haematol. 1997 Feb;96(2):374-6.

PMID:
9029028
14.

A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.

Jordan JH, Fritsche-Polanz R, Sperr WR, Mitterbauer G, Födinger M, Schernthaner GH, Christian Bankl H, Gebhart W, Chott A, Lechner K, Valent P.

Leuk Res. 2001 Jul;25(7):627-34.

PMID:
11377687
15.

Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.

Noack F, Escribano L, Sotlar K, Nunez R, Schuetze K, Valent P, Horny HP.

Leuk Lymphoma. 2003 Feb;44(2):313-9.

PMID:
12688351
16.

Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA.

Br J Haematol. 2007 Jul;138(1):12-30. Review.

PMID:
17555444
18.

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.

Zappulla JP, Dubreuil P, Desbois S, Létard S, Hamouda NB, Daëron M, Delsol G, Arock M, Liblau RS.

J Exp Med. 2005 Dec 19;202(12):1635-41. Epub 2005 Dec 13.

19.

Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.

Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, Mateo MB, Alonso Díaz de Durana MD, de la Hoz B, Del Pozo Gil MD, Caballero T, Rosado A, Sánchez Matas I, Teodósio C, Jara-Acevedo M, Mollejo M, García-Montero A, Orfao A, Escribano L.

J Allergy Clin Immunol. 2010 Jun;125(6):1269-1278.e2. doi: 10.1016/j.jaci.2010.02.019.

PMID:
20434205
20.

Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis.

Dror Y, Leaker M, Caruana G, Bernstein A, Freedman MH.

Br J Haematol. 2000 Mar;108(4):729-36.

PMID:
10792276
Items per page

Supplemental Content

Write to the Help Desk